Amgen's claims related to antibodies aimed at PCSK9, Regeneron and Sanofi said in a statement. PCSK9 is a gene that gives instructions for producing a protein that aids in regulating cholesterol, according to the US National Library of Medicine.
"Today's decision by the U.S. District Court for the District of Delaware validates our position that Amgen's patents are overly broad and invalid," Joseph LaRosa, Regeneron's general counsel said in a statement.
Price: 287.64, Change: 0.00, Percent Change: 0.00
|Insider Selling at Boston Beer (SAM) Continues with ...|
|CarGurus (CARG) sees Significant Insider Selling Con...|
|Insider at Ralph Lauren (RL) Makes Significant Sale ...|
|Insider Selling at Costco Wholesale (COST) is Signif...|
|Insider at American Tower (AMT) Makes Significant Sa...|